Physician - Hematologic Malignancies - Scientist - Immune Effector Cell Therapy
Reported by 17 physicians · region cohort · total comp, not the employer's posted pay
Overview
- Location
- Westwood, Kansas
- Schedule
- Full-time, research-track faculty
- SalaryDr Signal range
- $435k – $520k
- Practice
- Academic medical center / NCI-designated Comprehensive Cancer Center · Academic medical center (University of Kansas Health System)
17 physician reports · not the employer's posted pay
Role summary
The University of Kansas Health System and KU Cancer Center are seeking a full-time, research-track faculty Physician/Scientist in Immune Effector Cell Therapy within the Division of Hematologic Malignancies & Cellular Therapeutics, focused on translational CAR-T/CAR-NK research and early-phase clinical trials. The role is based at an NCI-designated Comprehensive Cancer Center within a 1,045-bed Level 1 trauma center academic medical center, with competitive salary, start-up support, and comprehensive benefits.
What the posting highlights
- Division of Hematologic Malignancies & Cellular Therapeutics; collaboration with cGMP manufacturing, IAMI, Clinical Trials Office, Pathology, and Biostatistics
- Care setting: Primarily research-track with clinical trial participation; clinical component involves hematologic malignancies and cellular therapeutics
- Patient population: Hematologic malignancy patients (and solid tumor patients in research context) across Kansas and western Missouri
- Research or clinical-trial participation is noted
SalaryDr summary based on the original posting
Posted base pay vs physician-reported total comp
Physician-reported range shown; the employer did not post pay for this role.
Compensation
- What physicians report
- $435k – $520k
- Pay context
- SalaryDr Signal · physician-reported
- Report sample
- 17 recent physician reports · region cohort
- Compensation basis
- Estimated total compensation
This is a SalaryDr Signal computed from 17 recent, approved physician reports (region cohort). It is not an employer offer or posted pay; this employer did not disclose pay.
Employer
University of Kansas Health System
Claim this free profile to see who's viewing your roles and manage your listings.
Facility & Community
- Practice setting
- Academic medical center / NCI-designated Comprehensive Cancer Center
- Facility type
- Academic medical center (University of Kansas Health System)
- Beds
- 1045
- Trauma level
- Level 1
- Patient population
- Hematologic malignancy patients (and solid tumor patients in research context) across Kansas and western Missouri
- EHR
- Not stated in posting
SalaryDr will show local peer compensation and hiring supply here once this role has enough physician-reported data.
Questions to ask the employer
- What is the call schedule, and is call compensated separately or built into the base?
- How many weeks of PTO and CME time are included, and is unused time paid out?
Generated from this posting's disclosed facts and the SalaryDr comparison — bring them to the first recruiter call.
Work Design
- Schedule
- Full-time, research-track faculty
- Shift type
- Standard academic/research schedule
- Inpatient / outpatient
- Primarily research-track with clinical trial participation; clinical component involves hematologic malignancies and cellular therapeutics
- Coverage model
- Division of Hematologic Malignancies & Cellular Therapeutics; collaboration with cGMP manufacturing, IAMI, Clinical Trials Office, Pathology, and Biostatistics
- Admin burden
- Regulatory documentation (IACUC/IRB, Biosafety, IND/IDE modules), grant writing, cross-functional project team coordination, faculty recruitment
- FTE
- 1
- Teaching
- Yes
- Research
- Yes
- Supervises APPs
- No
Visa & Eligibility
- Remote
- No
- J-1 waiver
- No
- H-1B
- No
Source & Verification
- Source
- Official employer source
- Salary label
- SalaryDr Signal
- First seen
- 5 mo ago
- Last verified
- today
- Extraction confidence
- 62%
Full description
The University of Kansas Health System and The University of Kansas Cancer Center, are seeking a Scientist in Immune Effector Cell Therapy to join the Division of Hematologic Malignancies & Cellular Therapeutics.
The University of Kansas Cancer Center (KUCC) is the only NCI-designated Comprehensive Cancer Center in the region, serving patients across Kansas and western Missouri. The program includes the region’s largest Blood and Marrow Transplant and Cellular Immunotherapy program, providing a strong clinical and translational platform for innovative immune effector cell research.
The selected candidate will benefit from exceptional institutional resources, including a new state-of-the-art cancer center currently under construction to support cutting-edge research and multidisciplinary care. This full-time, research-track faculty position offers academic rank commensurate with experience, competitive salary and comprehensive benefits, dedicated start-up support, and access to institutional core facilities within a highly collaborative campus environment.
This is a unique opportunity to shape the future of cancer immunotherapy by driving translational research at the interface of discovery science, preclinical development, and early-phase clinical trials. The successful candidate will contribute to next-generation immune effector strategies, including CAR-T and CAR-NK therapies, engineered macrophages/monocytes, and combination immunotherapies for hematologic and solid tumors.
Key Responsibilities:
- Establish an innovative and externally funded research program.
- Design, lead and execute translational studies in immune-effector cell therapy (e.g., CAR constructs, BiTEs, “armored” cells, logic-gated circuits) that enable generation of patentable IEC intellectual property.
- Recruit additional faculty to expand research within the IEC program.
- Design and oversee in vitro functional assays (killing, cytokine profiling, spectral flow, scRNA-seq/CITE-seq) and in vivo preclinical efficacy/toxicity models.
- Collaborate with KUCC’s cGMP manufacturing, the Institute for Advancing Medical Innovation (IAMI), Clinical Trials Office, Pathology, and Biostatistics to advance First-in-Human, enabling investigational new drug submissions to FDA and lead/participate in IEC early phase clinical trials.
- Develop and validate analytical/quality assays (potency, identity, vector copy number, sterility/mycoplasma, off-target/tropism assessments).
- Contribute to the preparation of regulatory documentation (IACUC/IRB, Biosafety, IND/IDE modules), study protocols, and clinical correlative science plans.
- Mentor trainees (graduate students, residents, postdocs and fellows) as well as junior faculty and coordinate cross-functional project teams.
- Disseminate results via manuscripts, conference abstracts, and grant applications (NIH, LLS, foundations).
Qualifications:
- MD, DO, MD/PhD, or PhD in Immunology, Hematology/Oncology; Cancer Biology, Bioengineering, or related field
- 2–5 years post-degree research experience in immune-effector cell therapy or closely related area
- Hands-on expertise in cell engineering (viral/non-viral delivery; CRISPR or equivalent), primary T/NK cell culture, and functional immunology assays
- Previous extramural funding: i.e., K award, R21, DOD
- Demonstrated track record of impactful publications and team-based science
Preferred Qualifications:
- Experience with CAR/TCR design, multiplex editing, payload/armoring strategies (e.g., IL-15, TGF-β-DN), or innate cell engineering (CAR-macrophage)
- Familiarity with GMP principles, release testing, and tech transfer to manufacturing
- Experience with glial/solid tumor models and strategies to overcome antigen heterogeneity/immune suppression
- Comfort with bioinformatics for single cell/NGS datasets and correlative biomarker discovery
- Prior participation in IND-enabling or early-phase clinical translation
Environment & Resources
KUCC offers integrated cGMP cell manufacturing, AAALAC-accredited vivaria, advanced cytometry (spectral flow, CyTOF), imaging cores, and biostatistics/bioinformatics support. The Division partners closely with clinical programs in hematologic malignancies and cellular therapeutics and IAMI to generate IEC discoveries and with the GMP lab, to accelerate bedside-to-bench-to-bedside translation.
Benefits and compensation
- Recent increase in overall compensation package
- Comprehensive retirement program
- Relocation assistance
- Health, dental, vision insurance with coverage day one
- CME allowance
- LTD/STD and Life insurance
- Professional liability insurance
About The University of Kansas Cancer Center
The University of Kansas Cancer Center (KUCC) is the only NCI-designated Comprehensive Cancer Center in the region, serving patients across Kansas and western Missouri. Our program includes the region’s largest Blood and Marrow Transplant and Cellular Immunotherapy program, offering a robust clinical platform to support innovative translational research.
The cancer center’s Hematologic Malignancies & Cellular Therapeutics (HMCT) division is the region’s largest and among the first in the nation to provide all FDA-approved CAR T-cell therapies. We perform more than 450 transplants annually. Our team is leading multiple efforts to advance novel immunotherapies, including a national effort for a new Phase 1 IND manufacturing a novel CD19/20/22 (NCT06879340).
Our new state-of-the-art facility, which will open early 2028, is purposefully designed to co-locate teams to promote collaboration. This significant investment includes a GMP manufacturing facility to advance cell and gene therapy innovation. With a robust infrastructure for rapid trial activation, data management and regulatory compliance, KUCC drives breakthroughs from bench to bedside. Through collaboration and patient-centered care, we are shaping the future of cancer treatment.
<…